International Paediatric Mitochondrial Disease Scale

[1]  Marni J. Falk,et al.  Inhibiting cytosolic translation and autophagy improves health in mitochondrial disease. , 2015, Human molecular genetics.

[2]  M. Zeviani,et al.  Emerging concepts in the therapy of mitochondrial disease. , 2015, Biochimica et biophysica acta.

[3]  L. Buydens,et al.  Quantifying small molecule phenotypic effects using mitochondrial morpho-functional fingerprinting and machine learning , 2015, Scientific Reports.

[4]  A. Bentivoglio,et al.  Reliability of Clinical Diagnosis of Dystonia , 2014, Neuroepidemiology.

[5]  J. Smeitink,et al.  Towards the harmonization of outcome measures in children with mitochondrial disorders , 2013, Developmental medicine and child neurology.

[6]  Alexis Wright,et al.  Clinimetrics corner: a closer look at the minimal clinically important difference (MCID) , 2012, The Journal of manual & manipulative therapy.

[7]  P. J. Valenciano,et al.  Correlation among the Visual Gait Assessment Scale, Edinburgh Visual Gait Scale and Observational Gait Scale in children with spastic diplegic cerebral palsy. , 2012, Revista brasileira de fisioterapia (Sao Carlos (Sao Paulo, Brazil)).

[8]  P. J. Valenciano,et al.  Correlação entre a Visual Gait Assessment Scale, Edinburgh Visual Gait Scale e Escala Observacional da Marcha em crianças com paralisia cerebral diparética espástica , 2012 .

[9]  Werner J H Koopman,et al.  Monogenic mitochondrial disorders. , 2012, The New England journal of medicine.

[10]  E. Schon,et al.  In Vivo Correction of COX Deficiency by Activation of the AMPK/PGC-1α Axis , 2011, Cell metabolism.

[11]  E. Zanoteli,et al.  Comparison of motor strength and function in patients with Duchenne muscular dystrophy with or without steroid therapy. , 2010, Arquivos de neuro-psiquiatria.

[12]  T. Wenz.  PGC‐1α activation as a therapeutic approach in mitochondrial disease , 2009, IUBMB life.

[13]  J. Smeitink,et al.  Mitochondrial medicine: entering the era of treatment , 2009, Journal of internal medicine.

[14]  J. Singerman,et al.  Consistency of the Babinski reflex and its variants , 2008, European journal of neurology.

[15]  G. Uziel,et al.  A scale to monitor progression and treatment of mitochondrial disease in children , 2006, Neuromuscular Disorders.

[16]  J. Fock,et al.  Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. , 2005, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[17]  S. Johnston,et al.  Should the Babinski sign be part of the routine neurologic examination? , 2005, Neurology.

[18]  Robert W. Taylor,et al.  The epidemiology of mitochondrial disorders--past, present and future. , 2004, Biochimica et biophysica acta.

[19]  D. Sutherland,et al.  Relationships Among Musculoskeletal Impairments and Functional Health Status in Ambulatory Cerebral Palsy , 2003, Journal of pediatric orthopedics.

[20]  J. M. Bevan,et al.  Measurement in Medicine. , 1971 .

[21]  Yung-Jung Chen,et al.  The intra- and inter-rater reliability of component analysis of rise from supine in the children with typical development and developmental delay. , 2014, Research in developmental disabilities.

[22]  S. Wortmann,et al.  Developing outcome measures for pediatric mitochondrial disorders: which complaints and limitations are most burdensome to patients and their parents? , 2013, Mitochondrion (Amsterdam. Print).

[23]  H. Vet,et al.  Measurement in Medicine: Index , 2011 .

[24]  B. Khatri.  Should the Babinski sign be part of the routine neurologic examination? , 2006, Neurology.

[25]  M. Hallett,et al.  Classification and definition of disorders causing hypertonia in childhood. , 2003, Pediatrics.

[26]  M. Hamilton,et al.  Measurement in Medicine , 1952, Nature.